CureVac (NASDAQ:CVAC) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

CureVac (NASDAQ:CVAC) announced its quarterly earnings data on Thursday. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01), Zacks reports. The business had revenue of $15.44 million for the quarter, compared to the consensus estimate of $6.40 million. CureVac had a net margin of 20.72% and a return on equity of 21.98%.

CureVac Stock Performance

Shares of CVAC stock traded up $0.33 during trading hours on Friday, reaching $3.19. The stock had a trading volume of 723,581 shares, compared to its average volume of 813,279. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.20 and a quick ratio of 6.19. The firm has a 50-day simple moving average of $3.13 and a 200-day simple moving average of $3.16. The firm has a market capitalization of $714.18 million, a PE ratio of 5.80 and a beta of 2.48. CureVac has a twelve month low of $2.22 and a twelve month high of $5.28.

Analyst Upgrades and Downgrades

Separately, JMP Securities reaffirmed a “market outperform” rating and set a $16.00 target price on shares of CureVac in a report on Friday, February 14th.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.